Location Directory

Clinical trials in Tampa, Florida

This page shows live ClinicalTrials.gov search results for Tampa, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3946

Shown on this page

Local exact-city summaries

3946

Based on exact city/state matches in the local index.

Local exact-city recruiting

793

Live official results below use the broader ClinicalTrials.gov location search.

The trial list below is retrieved from the live ClinicalTrials.gov search API for Tampa, Florida. Results on this page are currently sorted by Recently updated. Use the filter controls below to narrow by condition, treatment, sponsor, recruitment status, phase, study type, sex, or age.

Showing 1–12 of 3,946 matching trials in Tampa, FL.

Indexed local directory records.

The summary panels and records below use exact city/state matches from the local directory for Tampa, FL. Use the filters or full search link when you want broader live ClinicalTrials.gov location matching.

Top conditions in local exact-city summaries

Breast Cancer 86 Multiple Myeloma 62 Melanoma 61 Leukemia 57 Colorectal Cancer 56 Prostate Cancer 55

Top sponsors in local exact-city summaries

H. Lee Moffitt Cancer Center and Research Institute 319 National Cancer Institute (NCI) 191 Children's Oncology Group 157 Pfizer 129 Eli Lilly and Company 100 AstraZeneca 83

Top therapies in local exact-city summaries

Cyclophosphamide 119 Carboplatin 96 Pembrolizumab 93 Nivolumab 85 Cisplatin 68 Paclitaxel 63

Indexed official records

Open in full search

Conditions: Acute Stroke, Ischemic Stroke
Interventions: Zoom System; Device
Lead sponsor: Imperative Care, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 10
States / cities: Huntsville, Alabama • Walnut Creek, California • Tampa, Florida + 7 more

Conditions: Advanced Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Cancer, Metastatic Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer
Interventions: Chemotherapy Regimen 1, Chemotherapy Regimen 2, PF-08634404, Pembrolizumab; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 152
States / cities: Bullhead City, Arizona • Chandler, Arizona • Gilbert, Arizona + 124 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: Placebo, S-337395; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 33
States / cities: Los Angeles, California • Toluca Lake, California • Coral Gables, Florida + 19 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: COYA 302, Placebo; Drug
Lead sponsor: Coya Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more

Conditions: Epilepsy, Epilepsy (Treatment Refractory)
Interventions: Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system); Device
Lead sponsor: Epiminder America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 17
States / cities: Phoenix, Arizona • Irvine, California • Palo Alto, California + 13 more

Conditions: Locally Advanced Cervical Adenocarcinoma
Interventions: Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 243
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 193 more

Conditions: Endometrial Cancer, Malignant Solid Tumour
Interventions: Doxorubicin, Paclitaxel, Puxitatug Samrotecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 66
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 57 more

Conditions: Chronic Low Back Pain (CLBP), Obesity, Overweight
Interventions: Placebo, Retatrutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 25
States / cities: Chandler, Arizona • Tucson, Arizona • Fountain Valley, California + 22 more

Conditions: Follicular Lymphoma
Interventions: Bendamustine, Cyclophosphamide, Doxorubicin, Golcadomide, Lenalidomide, Prednisone/Prednisolone, Rituximab, Vincristine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 31
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 25 more

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions: Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, Ubamatamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 21
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 17 more

Conditions: Crohn's Disease
Interventions: SAR441566, SAR441566 matching Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 19
States / cities: Sun City, Arizona • Bristol, Connecticut • Clermont, Florida + 16 more

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Cyclophosphamide, Methotrexate (MTX), Mycophenolate mofetil (MMF), Ruxolitinib (Rux), Tacrolimus (Tac); Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 30
States / cities: Palo Alto, California • San Francisco, California • Miami, Florida + 23 more

Clinical trials in Tampa, Florida

Filter and sort this location

Top conditions in local exact-city summaries

Top sponsors in local exact-city summaries

Top therapies in local exact-city summaries

Indexed official records

Continuous Dual Aspiration Technique With Zoom System for Stroke

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

Study of COYA 302 for the Treatment of ALS

Diagnosing Epilepsy To EffeCT Change

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)